ABITEC has learned how to make great things happen with limited resources and a sharing culture, by forging expert alliances. The company is working with Professor Abu Serajuddin, an internationally renowned pharmaceutical specialist from the College of Pharmacy and Allied Health Professionals at St. John’s University in New York. Professor Serajuddin has a distinguished pedigree supported by over ten patents, many years in industry with market leaders like Bristol Myers and Novartis and over 70 peer reviewed published research papers. Together with ABITEC and his team of Master and Ph.D. students, Dr. Serajuddin pioneers studies focusing on basic and applied research using ABITEC’s functional lipid excipients for drug solubilisation and delivery. It’s a journey that began with a chat over coffee during a workshop attended by ABITEC’s Sr. Research Scientist Damon Dalrymple and Global Business Director, Dr. Donald Kelemen. Just a few months prior, the ABITEC senior team had formulated a plan to seek strategic collaborations and partnerships with key universities and industry leaders in specific areas of R&D; most notably excipients and lipid chemistry. The chat became the catalyst for a unique collaboration that has yielded exceptional success.
“This kind of partnership gives us access to basic science that we did not have the internal resources to commit to. By combining our expertise in this way we are providing real solutions to the pharmaceutical market, expanding our trustworthy reputation and ultimately building our brand. We have already had two peer reviewed articles published by Dr. Serajuddin and co-authored by Damon Dalrymple. We look at the long view of trends in drug formulization and delivery and help direct research that will solve problems for our industrial partners,” explains Dr. Kelemen.
The ABITEC strategic alliance is focusing on key areas such as providing soluble forms of drugs for research so they can be scientifically assessed for toxicology and efficacy and improved delivery systems for existing drugs with issues around bio compatibility and effective dosage. Damon, Donald and colleague Dr. Jim Williams, anticipate that by 2014, eight out of ten drugs will be based on biological proteins and their research is also taking them towards creating solid particles for oral treatment with drugs that could only previously be injected.
The speed with which ABITEC, its university partners and its industry clients are seeing results is relative. The journey to market for any drug is long and rightfully includes countless steps in research, testing and trials before it reaches the market but the collaborative partners play pivotal roles in ensuring that every step is a step in the right direction. The time, money and expertise that ABITEC invests in supporting the graduate students in its partnership program is a long term investment that pays dividends on many levels. “We are extremely pleased to be actively involved with the training of future pharmacology scientists and helping them complete their thesis and dissertations. We are building brand recognition and a bond between us and the scientist that could last the life of their entire career. We are extending the concept of strategic collaborations to embrace India and the UK and we are looking forward to great things to come,” concludes Dr. Kelemen.
Publications as a result of the strategic alliance with Dr. Serajuddin and St. John’s University:
- A Comparative Evaluation of Mono-, Di– and Triglyceride of Medium Chain Fatty Acids by Lipid/Surfactant/Water Phase Diagram, Solubility Determination and Dispersion Testing for Application in Pharmaceutical Dosage Form Development DOI 10.1007s 11095-011-0541-3
- Effect of Difference in Fatty Acid Chain Lengths of Medium Chain Lipids on Lipid/Surfactant/Water Phase Diagrams and Drug Solubility. J. Excipients and Food Chem. 2 (3) 2011